Adenocarcinoma — Trials

Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

9,697 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,751
Recruiting: 1,519
Ph III recruiting: 167
Growth YoY: +8.6%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,318)

clinicaltrialsPublishedShowing 101–150 of 1,276 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06233981	Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis	completed	Phase 2	30	Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER	1	Apr 17, 2026	clinicaltrials
NCT07529613	Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma(T-DXd_HER2Low)	completed	Phase 1 / Phase 2	30	National Cancer Center Hospital East